Combination serotonin specific reuptake inhibitor and serotonin 1A receptor partial agonist for reducing L-DOPA-induced dyskinesia
AssigneeThe Research Foundation for The State University of New York
InventorsChristopher Roy Bishop, Anthony West, Fredric Manfresson
Life of this patent
Estimating the term…
Abstract
A method of treating and attenuating L-DOPA-induced dyskinesia, comprising administering an effective dose of at least one pharmacological agent, e.g., vilazodone, having serotonin-specific reuptake inhibition (SSRI) and serotonin receptor 1A (5-HT1AR) partial agonism activity, in conjunction with L-DOPA. Other agents, such as an L-DOPA decarboxylase inhibitor, e.g., carbidopa, or other adjunct treatments may also be provided.
Claims20
A method of treating a L-DOPA-induced dyskinesia in a human patient, comprising daily administration of a pharmaceutically-acceptable dosage form containing vilazodone, in an amount of 2.5 to 5 mg per pharmaceutically-acceptable dosage form, concurrent with L-DOPA and for a sufficient duration, to treat the dyskinesia of the human patient and cause a downregulation of presynaptic 5-HT1A autoreceptors.
A method of treating an L-DOPA-induced dyskinesia in a human patient, comprising daily administration of a pharmaceutically-acceptable dosage form, comprising vilazodone in an amount of between 2.5 and 10 mg per pharmaceutically-acceptable dosage form of the daily administration concurrent with treatment with L-DOPA, to cause a downregulation of presynaptic 5-HT1A autoreceptors.
A method of treating a human who receives L-DOPA and suffers from L-DOPA-induced dyskinesia, comprising daily administration of 2.5 mg to 10 mg of a pharmaceutically acceptable dosage form of vilazodone to the human while also being treated with L-DOPA, to treat the L-DOPA induced dyskinesia and cause a downregulation of presynaptic 5-HT1A autoreceptors.
Dependencies are inferred from the claim text.